In terms of molecular characteristics, 86 patients (52.7%) displayed BRAF mutation (100% in the TT group vs. 7.4% in the IT group, p < 0.001), while 33 patients exhibited NRAS mutant melanoma (39.5% in the IT group vs. 1.2% in the TT group, p < 0.001). Here, NRAS is linked to melanoma.